Precipio (PRPO)
Pairs hematologic-cancer pathology testing with proprietary diagnostic products.
$26.27
After hours−0.13 (−0.47%)
At close$26.39(−1.49%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 4 | 3 | 4 | 5 | 5 | 4 | 6 | 6 | 8 | 6 | 7 |
| Cost of revenue | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 5 | 4 | 4 |
| Gross profit | 2 | 2 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | |
| Research & development | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 3 | 3 | 3 | 0 | 3 | 0 | −1 | 0 | 1 | 0 | 4 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 3 | 0 | 0 | 0 | 3 | 0 | −1 | 0 | 1 | 0 | 0 |
| Other expenses | 0 | −3 | 0 | 0 | 3 | −2 | 3 | 4 | 3 | 2 | 4 | 0 |
| Operating income | −1 | −1 | −2 | −1 | −1 | 0 | −1 | −1 | 0 | 1 | −1 | −1 |
| 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | −2 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | 1 | −2 | −1 | −1 | 0 | −1 | 0 | 0 | 1 | −1 | 0 |
| Net income from continuing operations | −1 | 1 | −2 | −1 | −1 | 0 | −1 | 0 | 0 | 1 | −1 | 0 |
| Net income | −1 | 1 | −2 | −1 | −1 | 0 | −1 | 0 | 0 | 1 | −1 | 0 |
| EPS, basic | −$1.04 | $0.65 | −$1.46 | −$0.83 | −$0.42 | −$0.25 | −$0.59 | $0.05 | −$0.05 | $0.33 | −$0.81 | −$0.12 |
| EPS, diluted | −$1.04 | $0.65 | −$1.46 | −$0.83 | −$0.42 | −$0.25 | −$0.59 | $0.05 | −$0.05 | $0.33 | −$0.81 | −$0.12 |
| Weighted average shares, basic | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Weighted average shares, diluted | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | −1 | 1 | −2 | −1 | 0 | 0 | 0 | 1 | 0 | 1 | −1 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| EBIT | −1 | 1 | −2 | −1 | −1 | 0 | −1 | 0 | 0 | 0 | −1 | 0 |